4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025)
4D Molecular Therapeutics (FDMT) reported Capital Expenditures of -$606000.0 for Q4 2025, up 73.97% year-over-year from -$348337.8 in Q4 2024, and down 565.93% quarter-over-quarter from -$91000.0 in Q3 2025.
4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 6 years of Capital Expenditures data on file, last reported at -$606000.0 in Q4 2025.
- Capital Expenditures for Q4 2025 came in at -$606000.0, up 73.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$140000.0 (down 129.51% YoY), and the FY2024 annual result was $509000.0, down 81.63% from the prior year.
- Capital Expenditures slipped to -$606000.0 in Q4 2025 per FDMT's latest filing, from -$91000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.7 million in Q3 2024 and troughed at -$2.3 million in Q4 2024.
- A 5-year average of $320800.0 and a median of $457000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures surged 4485.71% in 2021, then tumbled 204.71% in 2022.
- A 5-year view of Capital Expenditures shows it stood at $896000.0 in 2021, then fell by 28.57% to $640000.0 in 2022, then jumped by 279.06% to $2.4 million in 2023, then plunged by 195.96% to -$2.3 million in 2024, then soared by 73.97% to -$606000.0 in 2025.
- Business Quant data shows FDMT's Capital Expenditures at -$606000.0 in Q4 2025, -$91000.0 in Q3 2025, and $557000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -606,000.00 |
| Dec 31, 2025 | -606,000.00 |
| Sep 30, 2025 | -91,000.00 |
| Sep 30, 2025 | -91,000.00 |
| Jun 30, 2025 | 557,000.00 |
| Jun 30, 2025 | 557,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | -2.33 Mn |
| Dec 31, 2024 | -2.33 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | -533,000.00 |
| Jun 30, 2024 | -533,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Dec 31, 2023 | 2.43 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | -1.47 Mn |
| Sep 30, 2023 | -1.47 Mn |